Clinical Trial Update: A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating whether continuing enzalutamide beyond progression improves outcomes for men with metastatic castration-resistant prostate cancer who a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)

Snippet

Sponsor: Astellas Pharma Europe Ltd. | Conditions: Metastatic Castration Resistant Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2021-12-15